Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher complication rates and longer hospital stays than RP for non-metastatic PCa.
Identification of DNA repair defects within prostate cancer tissue may enable a precision oncologic approach to treatment.
From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.
Physicians increasingly are prescribing high dose and very high dose radiation therapy after radical prostatectomy despite an absence of randomized trials supporting the practice.
Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
Radiation therapy dose escalation, pelvic lymph node irradiation, and hormone therapy duration are prescribed based on patient and tumor characteristics.
Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.
Younger men with prostate cancer are less likely to experience Gleason score upgrading and pathologic progression on repeat biopsy.
According to researchers, 57.3% of men who underwent salvage robot-assisted radical prostatectomy were pad-free at 12 months.
New study shows no significant difference in overall survival between 18 and 36 months of androgen deprivation therapy used in combination with radiation therapy.
Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.
Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.
MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Pulmonary embolism is associated with GnRH agonist use and orchiectomy.
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.
Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.
aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer
More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015.
Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.
Men receiving enzalutamide plus ADT had a significant 71% lower risk for metastasis or death compared with men receiving placebo plus ADT.
Children who migrated to the UK from Bangladesh before puberty and Bangladeshis born in the UK had significantly higher levels of testosterone compared with life-long residents of Bangladesh.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Researchers question the generalizability of a major study showing no significant difference in cancer-specific and overall survival between surgery and observation for localized prostate cancer.
Men with advanced prostate cancer at diagnosis have an elevated risk of spinal cord compression, renal failure, and other cancer-related morbidities.
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Clinicians can rest easier about recommending finasteride to more men, according to experts.
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)